{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:03:52Z","timestamp":1790352232524,"version":"4.1.0"},"reference-count":207,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","award":["5507649"],"award-info":[{"award-number":["5507649"]}],"id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["U01HD085531-02"],"award-info":[{"award-number":["U01HD085531-02"]}],"id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001342","name":"Department of Science and Technology, Republic of South Africa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"DOI":"10.3389\/fmolb.2017.00075","type":"journal-article","created":{"date-parts":[[2017,11,14]],"date-time":"2017-11-14T04:23:43Z","timestamp":1510633423000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":55,"title":["Targeting DNA Replication and Repair for the Development of Novel Therapeutics against Tuberculosis"],"prefix":"10.3389","volume":"4","author":[{"given":"Michael A.","family":"Reiche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Digby F.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Mizrahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,11,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.molcel.2013.10.014","article-title":"A bacterial toxin inhibits DNA replication elongation through a direct interaction with the beta sliding clamp","volume":"52","author":"Aakre","year":"2013","journal-title":"Mol. Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17816","DOI":"10.1074\/jbc.M701841200","article-title":"Structure and function of DnaA N-terminal domains: specific sites and mechanisms in inter-DnaA interaction and in DnaB helicase loading on oriC","volume":"282","author":"Abe","year":"2007","journal-title":"J. Biol. Chem."},{"key":"B3","doi-asserted-by":"publisher","first-page":"7864","DOI":"10.3390\/molecules16097864","article-title":"Schiff bases of indoline-2, 3-dione: potential novel inhibitors of Mycobacterium tuberculosis (Mtb) DNA gyrase","volume":"16","author":"Aboul-Fadl","year":"2011","journal-title":"Molecules"},{"key":"B4","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.chembiol.2012.05.020","article-title":"Pathway-selective sensitization of Mycobacterium tuberculosis for target-based whole-cell screening","volume":"19","author":"Abrahams","year":"2012","journal-title":"Chem. Biol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/j.bmcl.2007.02.056","article-title":"Small molecule inhibitors of E. coli primase, a novel bacterial target","volume":"17","author":"Agarwal","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.cell.2017.06.025","article-title":"Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13","volume":"170","author":"Aggarwal","year":"2017","journal-title":"Cell"},{"key":"B7","doi-asserted-by":"publisher","first-page":"4466","DOI":"10.1016\/j.bmc.2009.05.014","article-title":"Discovery, characterization and comparison of inhibitors of Bacillus anthracis and Staphylococcus aureus replicative DNA helicases","volume":"17","author":"Aiello","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.MGM2-0031-2013","article-title":"The spectrum of drug susceptibility in mycobacteria","author":"Aldridge","year":"2014","journal-title":"Microbiol. Spectr."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1128\/AAC.46.4.1022-1025.2002","article-title":"In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis","volume":"46","author":"Alvirez-Freites","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1021\/jm0310232","article-title":"New antibacterial agents derived from the DNA gyrase inhibitor cyclothialidine","volume":"47","author":"Angehrn","year":"2004","journal-title":"J. Med. Chem."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1021\/jm1014023","article-title":"A new DNA gyrase inhibitor subclass of the cyclothialidine family based on a bicyclic dilactam-lactone scaffold. Synthesis and antibacterial properties","volume":"54","author":"Angehrn","year":"2011","journal-title":"J. Med. Chem."},{"key":"B12","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.compbiolchem.2005.07.001","article-title":"Potential drug targets in Mycobacterium tuberculosis through metabolic pathway analysis","volume":"29","author":"Anishetty","year":"2005","journal-title":"Comput. Biol. Chem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.ijmyco.2016.08.009","article-title":"New insights into the mechanism of action of pyrazinamide, implications for susceptibility testing, and future regimens","volume":"5","author":"Anthony","year":"2016","journal-title":"Int. J. Mycobacteriol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1128\/AAC.48.4.1281-1288.2004","article-title":"Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity","volume":"48","author":"Aubry","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.tim.2017.05.007","article-title":"Antimycobacterial metabolism: illuminating mycobacterium tuberculosis biology and drug discovery","volume":"25","author":"Awasthi","year":"2017","journal-title":"Trends Microbiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/imr.12267","article-title":"New insights into TB physiology suggest untapped therapeutic opportunities","volume":"264","author":"Baer","year":"2015","journal-title":"Immunol. Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/s41467-017-00886-w","article-title":"High-fidelity DNA replication in Mycobacterium tuberculosis relies on a trinuclear zinc center","volume":"8","author":"Banos-Mateos","year":"2017","journal-title":"Nat. Commun."},{"key":"B18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/978-3-319-28368-5_5","article-title":"DNA-synthesizing enzymes as antibacterial targets","volume-title":"New Weapons to Control Bacterial Growth","author":"Barreiro","year":"2016"},{"key":"B19","doi-asserted-by":"publisher","first-page":"9078","DOI":"10.1021\/jm501174m","article-title":"Novel DNA gyrase inhibiting spiropyrimidinetriones with a benzisoxazole scaffold: SAR and in vivo characterization","volume":"57","author":"Basarab","year":"2014","journal-title":"J. Med. Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"6264","DOI":"10.1021\/acs.jmedchem.5b00863","article-title":"Discovery of novel DNA gyrase inhibiting spiropyrimidinetriones: benzisoxazole fusion with N-Linked oxazolidinone substituents leading to a clinical candidate (ETX0914)","volume":"58","author":"Basarab","year":"2015","journal-title":"J. Med. Chem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1128\/microbiolspec.MGM2-0026-2013","article-title":"Metabolomics of central carbon metabolism in Mycobacterium tuberculosis","author":"Baughn","year":"2014","journal-title":"Microbiol. Spectr"},{"key":"B22","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/nature09197","article-title":"Type IIA topoisomerase inhibition by a new class of antibacterial agents","volume":"466","author":"Bax","year":"2010","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3389\/fmicb.2015.00562","article-title":"A Replisome's journey through the bacterial chromosome","volume":"6","author":"Beattie","year":"2015","journal-title":"Front. Microbiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e21763","DOI":"10.7554\/eLife.21763","article-title":"Frequent exchange of the DNA polymerase during bacterial chromosome replication","volume":"6","author":"Beattie","year":"2017","journal-title":"Elife"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1128\/AAC.00496-08","article-title":"Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases","volume":"52","author":"Black","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1128\/AAC.03913-14","article-title":"Mycobacterium tuberculosis gyrase inhibitors as a new class of antitubercular drugs","volume":"59","author":"Blanco","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1126\/science.aag1006","article-title":"Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420","volume":"355","author":"Blondiaux","year":"2017","journal-title":"Science"},{"key":"B28","doi-asserted-by":"publisher","first-page":"40174","DOI":"10.1074\/jbc.M406796200","article-title":"The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action","volume":"279","author":"Boshoff","year":"2004","journal-title":"J. Biol. Chem."},{"key":"B29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0092-8674(03)00270-8","article-title":"DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis","volume":"113","author":"Boshoff","year":"2003","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/nrmicro.2016.34","article-title":"Distinguishing between resistance, tolerance and persistence to antibiotic treatment","volume":"14","author":"Brauner","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"39435","DOI":"10.1074\/jbc.M306479200","article-title":"Specific and potent inhibition of NAD+-dependent DNA ligase by pyridochromanones","volume":"278","author":"Brotz-Oesterhelt","year":"2003","journal-title":"J. Biol. Chem."},{"key":"B32","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.2174\/1381612819666131118170238","article-title":"New tuberculostatic agents targeting nucleic acid biosynthesis: drug design using QSAR approaches","volume":"20","author":"Bueno","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"B33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1128\/AAC.01311-05","article-title":"Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound","volume":"51","author":"Butler","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1021\/ml300169x","article-title":"Antimicrobial Activity of Adenine-Based Inhibitors of NAD+-Dependent DNA Ligase","volume":"3","author":"Buurman","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"B35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ijmyco.2015.02.002","article-title":"Benzothiazinone-piperazine derivatives as efficient Mycobacterium tuberculosis DNA gyrase inhibitors","volume":"4","author":"Chandran","year":"2015","journal-title":"Int. J. Mycobacteriol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s10930-010-9302-0","article-title":"Inhibition of Klebsiella pneumoniae DnaB helicase by the flavonol galangin","volume":"30","author":"Chen","year":"2011","journal-title":"Protein J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.6026\/97320630006069","article-title":"DNA polymerase III alpha subunit from Mycobacterium tuberculosis H37Rv: homology modeling and molecular docking of its inhibitor","volume":"6","author":"Chhabra","year":"2011","journal-title":"Bioinformation"},{"key":"B38","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/jac\/dkr449","article-title":"Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis","volume":"67","author":"Chopra","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1021\/np0302302","article-title":"Isolation and structure elucidation of Sch 642305, a novel bacterial DNA primase inhibitor produced by Penicillium verrucosum","volume":"66","author":"Chu","year":"2003","journal-title":"J. Nat. Prod."},{"key":"B40","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1128\/AAC.43.11.2766","article-title":"Specific inhibition of the eubacterial DNA ligase by arylamino compounds","volume":"43","author":"Ciarrocchi","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"B41","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nchembio.2007.24","article-title":"Targeting virulence: a new paradigm for antimicrobial therapy","volume":"3","author":"Clatworthy","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/31159","article-title":"Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence","volume":"393","author":"Cole","year":"1998","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.smim.2014.09.012","article-title":"Consequences of genomic diversity in Mycobacterium tuberculosis","volume":"26","author":"Coscolla","year":"2014","journal-title":"Semin. Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nrmicro3200","article-title":"The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells","volume":"12","author":"Dartois","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1016\/j.bmcl.2013.07.006","article-title":"A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis","volume":"23","author":"Dartois","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e02133-16","DOI":"10.1128\/mBio.02133-16","article-title":"Comprehensive essentiality analysis of the Mycobacterium tuberculosis Genome via saturating transposon mutagenesis","volume":"8","author":"DeJesus","year":"2017","journal-title":"MBio"},{"key":"B47","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S2213-2600(14)70031-1","article-title":"Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis","volume":"2","author":"Dheda","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S2213-2600(17)30079-6","article-title":"The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis","volume":"5","author":"Dheda","year":"2017","journal-title":"Lancet Respir. Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.bmcl.2007.11.110","article-title":"Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation","volume":"18","author":"Dinakaran","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1128\/AAC.01545-09","article-title":"In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species","volume":"54","author":"Disratthakit","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"B51","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1128\/microbiolspec.TBTB2-0027-2016","article-title":"DNA Replication in Mycobacterium tuberculosis","author":"Ditse","year":"2017","journal-title":"Microbiol. Spectr"},{"key":"B52","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1146\/annurev-pharmtox-010814-124712","article-title":"Unraveling the physiological complexities of antibiotic lethality","volume":"55","author":"Dwyer","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.drudis.2011.02.002","article-title":"Fragment screening to predict druggability (ligandability) and lead discovery success","volume":"16","author":"Edfeldt","year":"2011","journal-title":"Drug Discov. Today"},{"key":"B54","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1021\/acsinfecdis.7b00006","article-title":"A phenotypic based target screening approach delivers new antitubercular CTP synthetase inhibitors","volume":"3","author":"Esposito","year":"2017","journal-title":"ACS Infect. Dis."},{"key":"B55","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/cbdd.12549","article-title":"Improving the tuberculosis drug development pipeline","volume":"86","author":"Evangelopoulos","year":"2015","journal-title":"Chem. Biol. Drug Des."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1099\/mic.0.X00002-0","article-title":"Mycobacterium tuberculosis thymidylate synthase gene thyX is essential and potentially bifunctional, while thyA deletion confers resistance to p-aminosalicylic acid","volume":"158","author":"Fivian-Hughes","year":"2012","journal-title":"Microbiol. Sgm"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1128\/AAC.49.3.1093-1100.2005","article-title":"Simocyclinone D8, an inhibitor of DNA gyrase with a novel mode of action","volume":"49","author":"Flatman","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"B58","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/ja.2014.131","article-title":"Antimycobacterial activity of DNA intercalator inhibitors of Mycobacterium tuberculosis primase DnaG","volume":"68","author":"Gajadeera","year":"2015","journal-title":"J. Antibiot. (Tokyo)"},{"key":"B59","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrg3664","article-title":"Genomic insights into tuberculosis","volume":"15","author":"Galagan","year":"2014","journal-title":"Nat. Rev. Genet"},{"key":"B60","doi-asserted-by":"publisher","first-page":"11116","DOI":"10.1073\/pnas.0804754105","article-title":"Structure of a small-molecule inhibitor of a DNA polymerase sliding clamp","volume":"105","author":"Georgescu","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B61","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1093\/jac\/dki191","article-title":"Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates","volume":"56","author":"Gillespie","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis","volume":"371","author":"Gillespie","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1093\/jac\/dkw340","article-title":"Identification of inhibitors for single-stranded DNA-binding proteins in eubacteria","volume":"71","author":"Glanzer","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"B64","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.bbrc.2014.03.029","article-title":"Inhibition of Mycobacterium tuberculosis topoisomerase I by m-AMSA, a eukaryotic type II topoisomerase poison","volume":"446","author":"Godbole","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1128\/AAC.04516-14","article-title":"Targeting Mycobacterium tuberculosis topoisomerase I by small-molecule inhibitors","volume":"59","author":"Godbole","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B66","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1128\/microbiolspec.TBTB2-0031-2016","article-title":"Targeting phenotypically tolerant Mycobacterium tuberculosis","author":"Gold","year":"2017","journal-title":"Microbiol. Spectr"},{"key":"B67","doi-asserted-by":"publisher","first-page":"20594","DOI":"10.1074\/jbc.M401841200","article-title":"Biochemical and genetic analysis of the four DNA ligases of mycobacteria","volume":"279","author":"Gong","year":"2004","journal-title":"J. Biol. Chem."},{"key":"B68","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0378-1119(96)00350-2","article-title":"Construction by homologous recombination and phenotypic characterization of a DNA polymerase domain polA mutant of Mycobacterium smegmatis","volume":"178","author":"Gordhan","year":"1996","journal-title":"Gene"},{"key":"B69","doi-asserted-by":"publisher","first-page":"7203","DOI":"10.1016\/j.bmc.2007.07.057","article-title":"Myricetin inhibits Escherichia coli DnaB helicase but not primase","volume":"15","author":"Griep","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e1002251","DOI":"10.1371\/journal.ppat.1002251","article-title":"High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism","volume":"7","author":"Griffin","year":"2011","journal-title":"PLoS Pathog."},{"key":"B71","doi-asserted-by":"publisher","first-page":"8792","DOI":"10.1021\/jm500563g","article-title":"Second-generation antibacterial benzimidazole ureas: discovery of a preclinical candidate with reduced metabolic liability","volume":"57","author":"Grillot","year":"2014","journal-title":"J. Med. Chem."},{"key":"B72","doi-asserted-by":"publisher","first-page":"18418","DOI":"10.1038\/srep18418","article-title":"The b2 clamp in the Mycobacterium tuberculosis DNA polymerase III ab2e replicase promotes polymerization and reduces exonuclease activity","volume":"6","author":"Gu","year":"2016","journal-title":"Sci. Rep."},{"key":"B73","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1016\/j.bmcl.2012.04.037","article-title":"Design, synthesis and biological evaluation of potent NAD+-dependent DNA ligase inhibitors as potential antibacterial agents. Part I: aminoalkoxypyrimidine carboxamides","volume":"22","author":"Gu","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B74","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.bmcl.2008.12.038","article-title":"Quinazolin-2-ylamino-quinazolin-4-ols as novel non-nucleoside inhibitors of bacterial DNA polymerase III","volume":"19","author":"Guiles","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B75","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1128\/AAC.01751-13","article-title":"Optimization of pyrrolamides as mycobacterial GyrB ATPase inhibitors: structure-activity relationship and in vivo efficacy in a mouse model of tuberculosis","volume":"58","author":"Hameed","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B76","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1016\/j.bmcl.2004.02.006","article-title":"Two new bacterial DNA primase inhibitors from the plant Polygonum cuspidatum","volume":"14","author":"Hegde","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B77","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.copbio.2017.03.023","article-title":"Novel and revisited approaches in antituberculosis drug discovery","volume":"48","author":"Herrmann","year":"2017","journal-title":"Curr. Opin. Biotechnol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nrd892","article-title":"The druggable genome","volume":"1","author":"Hopkins","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"B79","doi-asserted-by":"publisher","first-page":"13637","DOI":"10.1038\/srep13637","article-title":"Selective in vivo and in vitro activities of 3,3\u2032-4-nitrobenzylidene-bis-4-hydroxycoumarin against methicillin-resistant Staphylococcus aureus by inhibition of DNA polymerase III","volume":"5","author":"Hou","year":"2015","journal-title":"Sci. Rep."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1021\/ml4003277","article-title":"Fragment-based discovery of 6-azaindazoles as inhibitors of bacterial DNA ligase","volume":"4","author":"Howard","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"B81","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10930-015-9609-y","article-title":"Inhibition of Staphylococcus aureus PriA Helicase by Flavonol Kaempferol","volume":"34","author":"Huang","year":"2015","journal-title":"Protein J."},{"key":"B82","doi-asserted-by":"publisher","first-page":"5087","DOI":"10.1016\/j.bmcl.2008.07.117","article-title":"Synthesis and antibacterial activity of the C-7 side chain of 3-aminoquinazolinediones","volume":"18","author":"Hutchings","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e0119760","DOI":"10.1371\/journal.pone.0119760","article-title":"In silico screening for novel inhibitors of DNA polymerase III alpha subunit of Mycobacterium tuberculosis (MtbDnaE2, H37Rv)","volume":"10","author":"Jadaun","year":"2015","journal-title":"PLoS ONE"},{"key":"B84","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.bmc.2014.12.001","article-title":"Exploring the gyrase ATPase domain for tailoring newer anti-tubercular drugs: hit to lead optimization of a novel class of thiazole inhibitors","volume":"23","author":"Jeankumar","year":"","journal-title":"Bioorg. Med. Chem."},{"key":"B85","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ijantimicag.2013.12.006","article-title":"Development of novel N-linked aminopiperidine-based mycobacterial DNA gyrase B inhibitors: scaffold hopping from known antibacterial leads","volume":"43","author":"Jeankumar","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B86","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ejmech.2013.09.025","article-title":"Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors","volume":"70","author":"Jeankumar","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"B87","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1039\/c4ob02049a","article-title":"Enabling the (3 + 2) cycloaddition reaction in assembling newer anti-tubercular lead acting through the inhibition of the gyrase ATPase domain: lead optimization and structure activity profiling","volume":"13","author":"Jeankumar","year":"","journal-title":"Org. Biomol. Chem."},{"key":"B88","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ejmech.2016.06.042","article-title":"Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors","volume":"122","author":"Jeankumar","year":"","journal-title":"Eur. J. Med. Chem."},{"key":"B89","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/cmdc.201500556","article-title":"Structure-guided discovery of antitubercular agents that target the gyrase ATPase domain","volume":"11","author":"Jeankumar","year":"","journal-title":"Chem. Med. Chem."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","article-title":"High-dose rifapentine with moxifloxacin for pulmonary tuberculosis","volume":"371","author":"Jindani","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"8834","DOI":"10.1021\/jm401268f","article-title":"Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B","volume":"56","author":"Kale","year":"2013","journal-title":"J. Med. Chem."},{"key":"B92","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.bmcl.2013.12.080","article-title":"Thiazolopyridone ureas as DNA gyrase B inhibitors: optimization of antitubercular activity and efficacy","volume":"24","author":"Kale","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B93","doi-asserted-by":"publisher","first-page":"5149","DOI":"10.1074\/jbc.M112.419069","article-title":"The naphthoquinone diospyrin is an inhibitor of DNA gyrase with a novel mechanism of action","volume":"288","author":"Karkare","year":"2013","journal-title":"J. Biol. Chem."},{"key":"B94","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1039\/c4ob01926a","article-title":"Phototriggerable peptidomimetics for the inhibition of Mycobacterium tuberculosis ribonucleotide reductase by targeting protein-protein binding","volume":"13","author":"Karlsson","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"B95","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.pep.2009.09.006","article-title":"Expression, purification and characterization of UvrD2 helicase from Mycobacterium tuberculosis","volume":"69","author":"Kazarian","year":"2010","journal-title":"Protein Expr. Purif."},{"key":"B96","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3109\/10409238.2013.869543","article-title":"Persisters and beyond: mechanisms of phenotypic drug resistance and drug tolerance in bacteria","volume":"49","author":"Kester","year":"2014","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"e1000976","DOI":"10.1371\/journal.pcbi.1000976","article-title":"The Mycobacterium tuberculosis drugome and its polypharmacological implications","volume":"6","author":"Kinnings","year":"2010","journal-title":"PLoS Comput. Biol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1126\/science.aaa4690","article-title":"Targeting DnaN for tuberculosis therapy using novel griselimycins","volume":"348","author":"Kling","year":"2015","journal-title":"Science"},{"key":"B99","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1038\/emi.2014.17","article-title":"The impact of drug resistance on Mycobacterium tuberculosis physiology: what can we learn from rifampicin?","volume":"3","author":"Koch","year":"2014","journal-title":"Emerg. Microbes Infect."},{"key":"B100","doi-asserted-by":"publisher","first-page":"4847","DOI":"10.1021\/jm2004688","article-title":"Synthesis and evaluation of 5-substituted 2'-deoxyuridine monophosphate analogues as inhibitors of flavin-dependent thymidylate synthase in Mycobacterium tuberculosis","volume":"54","author":"Kogler","year":"2011","journal-title":"J. Med. Chem."},{"key":"B101","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3390\/molecules22010154","article-title":"Naphthalimides selectively inhibit the activity of bacterial, replicative DNA Ligases and Display Bactericidal Effects against Tubercle Bacilli","volume":"22","author":"Korycka-Machala","year":"2017","journal-title":"Molecules"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1128\/AAC.01721-13","article-title":"Evaluation of DNA primase DnaG as a potential target for antibiotics","volume":"58","author":"Kuron","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B103","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nrc2998","article-title":"DNA polymerases and cancer","volume":"11","author":"Lange","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"B104","doi-asserted-by":"publisher","first-page":"e23932","DOI":"10.7554\/eLife.23932","article-title":"Single-molecule visualization of fast polymerase turnover in the bacterial replisome","volume":"6","author":"Lewis","year":"2017","journal-title":"Elife"},{"key":"B105","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/j.1460-2075.1996.tb00483.x","article-title":"The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X-ray crystallography","volume":"15","author":"Lewis","year":"1996","journal-title":"EMBO J."},{"key":"B106","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1016\/j.bmcl.2013.04.055","article-title":"Optimization of a novel potent and selective bacterial DNA helicase inhibitor scaffold from a high throughput screening hit","volume":"23","author":"Li","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B107","doi-asserted-by":"publisher","first-page":"10896","DOI":"10.1021\/jm300922h","article-title":"Coumarin-based inhibitors of Bacillus anthracis and Staphylococcus aureus replicative DNA helicase: chemical optimization, biological evaluation, and antibacterial activities","volume":"55","author":"Li","year":"2012","journal-title":"J. Med. Chem."},{"key":"B108","doi-asserted-by":"publisher","first-page":"735368","DOI":"10.1155\/2012\/735368","article-title":"Characterization of flavonol inhibition of DnaB helicase: real-time monitoring, structural modeling, and proposed mechanism","volume":"2012","author":"Lin","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1126\/science.1153018","article-title":"A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence","volume":"319","author":"Liu","year":"2008","journal-title":"Science"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1128\/AAC.04347-14","article-title":"A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections","volume":"59","author":"Locher","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B111","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/978-1-4939-2398-4_6","article-title":"Identifying essential genes in Mycobacterium tuberculosis by global phenotypic profiling","volume":"1279","author":"Long","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1073\/pnas.0909191107","article-title":"Small-molecule tools for dissecting the roles of SSB\/protein interactions in genome maintenance","volume":"107","author":"Lu","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B113","doi-asserted-by":"publisher","first-page":"4708","DOI":"10.1016\/j.bmcl.2006.12.065","article-title":"Design, synthesis, and structure-activity relationship studies of new phenolic DNA gyrase inhibitors","volume":"17","author":"Lubbers","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B114","doi-asserted-by":"publisher","first-page":"7521","DOI":"10.1039\/C7SC02622F","article-title":"Biosynthesis of methyl-proline containing griselimycins, natural products with anti-tuberculosis activity","volume":"8","author":"Lukat","year":"2017","journal-title":"Chem. Sci"},{"key":"B115","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1128\/MMBR.00055-15","article-title":"Bacterial transcription as a target for antibacterial drug development","volume":"80","author":"Ma","year":"2016","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"B116","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.plasmid.2009.11.002","article-title":"ppGpp inhibits the activity of Escherichia coli DnaG primase","volume":"63","author":"Maci\u0105g","year":"2010","journal-title":"Plasmid"},{"key":"B117","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/emmm.201303575","article-title":"Towards a new combination therapy for tuberculosis with next generation benzothiazinones","volume":"6","author":"Makarov","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"B118","doi-asserted-by":"publisher","first-page":"e58765","DOI":"10.1371\/journal.pone.0058765","article-title":"Protein interactions in genome maintenance as novel antibacterial targets","volume":"8","author":"Marceau","year":"2013","journal-title":"PLoS ONE"},{"key":"B119","doi-asserted-by":"publisher","first-page":"e466","DOI":"10.1371\/journal.pmed.0030466","article-title":"OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice","volume":"3","author":"Matsumoto","year":"2006","journal-title":"PLoS Med."},{"key":"B120","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1146\/annurev-biochem-061208-091655","article-title":"DNA replicases from a bacterial perspective","volume":"80","author":"McHenry","year":"2011","journal-title":"Annu. Rev. Biochem."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.bmcl.2005.11.076","article-title":"Triaminotriazine DNA helicase inhibitors with antibacterial activity","volume":"16","author":"McKay","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B122","doi-asserted-by":"publisher","first-page":"a021154","DOI":"10.1101\/cshperspect.a021154","article-title":"The tuberculosis drug discovery and development pipeline and emerging drug targets","volume":"5","author":"Mdluli","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B123","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.bmc.2016.01.011","article-title":"Development of acridine derivatives as selective Mycobacterium tuberculosis DNA gyrase inhibitors","volume":"24","author":"Medapi","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"B124","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1016\/j.bmc.2015.03.004","article-title":"Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors","volume":"23","author":"Medapi","year":"","journal-title":"Bioorg. Med. Chem."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejmech.2015.06.032","article-title":"4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: structural optimization, synthesis and biological evaluation","volume":"103","author":"Medapi","year":"","journal-title":"Eur. J. Med. Chem."},{"key":"B126","doi-asserted-by":"publisher","first-page":"5258","DOI":"10.1111\/j.1742-4658.2008.06652.x","article-title":"Identification and characterization of an inhibitor specific to bacterial NAD+-dependent DNA ligases","volume":"275","author":"Meier","year":"2008","journal-title":"FEBS J."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1056\/NEJMoa1315817","article-title":"A four-month gatifloxacin-containing regimen for treating tuberculosis","volume":"371","author":"Merle","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B128","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1128\/AAC.00247-08","article-title":"Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors","volume":"52","author":"Miller","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1128\/AAC.01181-10","article-title":"Novel bacterial NAD+-dependent DNA ligase inhibitors with broad-spectrum activity and antibacterial efficacy in vivo","volume":"55","author":"Mills","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"B130","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1128\/AAC.00647-15","article-title":"Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistance","volume":"59","author":"Minato","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B131","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1046\/j.1365-2958.1998.01038.x","article-title":"DNA repair in Mycobacterium tuberculosis. What have we learnt from the genome sequence?","volume":"29","author":"Mizrahi","year":"1998","journal-title":"Mol. Microbiol."},{"key":"B132","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1093\/nar\/24.24.4845","article-title":"Deoxy- and dideoxynucleotide discrimination and identification of critical 5\u2032 nuclease domain residues of the DNA polymerase I from Mycobacterium tuberculosis","volume":"24","author":"Mizrahi","year":"1996","journal-title":"Nucleic Acids Res."},{"key":"B133","doi-asserted-by":"crossref","first-page":"25178","DOI":"10.1074\/jbc.271.41.25178","article-title":"Molecular design of inhibitors of in vitro oriC DNA replication based on the potential to block the ATP binding of DnaA protein","volume":"271","author":"Mizushima","year":"1996","journal-title":"J. Biol. Chem."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1016\/j.bmc.2013.01.020","article-title":"Novel pseudopeptides incorporating a benzodiazepine-based turn mimetic\u2013targeting Mycobacterium tuberculosis ribonucleotide reductase","volume":"21","author":"Nurbo","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"B135","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.sbi.2005.12.004","article-title":"Clamp loaders and replication initiation","volume":"16","author":"O'Donnell","year":"2006","journal-title":"Curr. Opin. Struct. Biol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"16076","DOI":"10.1038\/nrdp.2016.76","article-title":"Tuberculosis","volume":"2","author":"Pai","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.chembiol.2015.08.015","article-title":"Elucidation of DnaE as the antibacterial target of the natural Product, Nargenicin","volume":"22","author":"Painter","year":"2015","journal-title":"Chem. Biol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1021\/acsinfecdis.6b00103","article-title":"Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against Mycobacterium tuberculosis","volume":"3","author":"Park","year":"2017","journal-title":"ACS Infect. Dis"},{"key":"B139","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nrd2201","article-title":"Drugs for bad bugs: confronting the challenges of antibacterial discovery","volume":"6","author":"Payne","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/nm.3262","article-title":"Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis","volume":"19","author":"Pethe","year":"2013","journal-title":"Nat. Med."},{"key":"B141","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.2174\/1568026617666170130114342","article-title":"Mycobacterial DNA replication as a target for antituberculosis drug discovery","volume":"17","author":"Plocinska","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/nm.3937","article-title":"The association between sterilizing activity and drug distribution into tuberculosis lesions","volume":"21","author":"Prideaux","year":"2015","journal-title":"Nat. Med."},{"key":"B143","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1128\/JB.01390-10","article-title":"The sporulation protein SirA inhibits the binding of DnaA to the origin of replication by contacting a patch of clustered amino acids","volume":"193","author":"Rahn-Lee","year":"2011","journal-title":"J. Bacteriol."},{"key":"B144","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.tube.2015.05.004","article-title":"Genetic and chemical validation identifies Mycobacterium tuberculosis topoisomerase I as an attractive anti-tubercular target","volume":"95","author":"Ravishankar","year":"2015","journal-title":"Tuberculosis (Edinb)."},{"key":"B145","doi-asserted-by":"publisher","first-page":"6552","DOI":"10.1016\/j.bmc.2014.10.016","article-title":"An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis DNA GyrB inhibition","volume":"22","author":"Reddy","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"B146","doi-asserted-by":"publisher","first-page":"8327","DOI":"10.1073\/pnas.0503272102","article-title":"Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages","volume":"102","author":"Rengarajan","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B147","doi-asserted-by":"publisher","first-page":"4924","DOI":"10.1016\/j.bmc.2014.06.041","article-title":"Design, synthesis, biological evaluation of substituted benzofurans as DNA gyraseB inhibitors of Mycobacterium tuberculosis","volume":"22","author":"Renuka","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"B148","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1146\/annurev-genet-110711-155421","article-title":"Chromosome replication and segregation in bacteria","volume":"46","author":"Reyes-Lamothe","year":"2012","journal-title":"Annu. Rev. Genet."},{"key":"B149","doi-asserted-by":"publisher","first-page":"352","DOI":"10.2174\/138945012799424598","article-title":"Architecture and conservation of the bacterial DNA replication machinery, an underexploited drug target","volume":"13","author":"Robinson","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"B150","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/ng.3269","article-title":"DNA replication fidelity in Mycobacterium tuberculosis is mediated by an ancestral prokaryotic proofreader","volume":"47","author":"Rock","year":"2015","journal-title":"Nat. Genet."},{"key":"B151","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.bmcl.2005.11.009","article-title":"Novel non-nucleobase inhibitors of Staphylococcus aureus DNA polymerase IIIC","volume":"16","author":"Rose","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B152","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1128\/AAC.00288-16","article-title":"Small-molecule inhibitors targeting topoisomerase I as novel antituberculosis agents","volume":"60","author":"Sandhaus","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B153","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1517\/17460441.2012.660478","article-title":"Bacterial DNA replication enzymes as targets for antibacterial drug discovery","volume":"7","author":"Sanyal","year":"2012","journal-title":"Exp. Opin. Drug Discov."},{"key":"B154","doi-asserted-by":"publisher","first-page":"12989","DOI":"10.1073\/pnas.2134250100","article-title":"Genetic requirements for mycobacterial survival during infection","volume":"100","author":"Sassetti","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B155","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1046\/j.1365-2958.2003.03425.x","article-title":"Genes required for mycobacterial growth defined by high density mutagenesis","volume":"48","author":"Sassetti","year":"2003","journal-title":"Mol. Microbiol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.bmc.2015.02.032","article-title":"Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain","volume":"23","author":"Saxena","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"B157","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1046\/j.1365-2958.2000.02096.x","article-title":"The interaction domains of the DnaA and DnaB replication proteins of Escherichia coli","volume":"37","author":"Seitz","year":"2000","journal-title":"Mol. Microbiol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1016\/j.bmc.2007.11.050","article-title":"Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1, 4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids","volume":"16","author":"Senthilkumar","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"B159","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1021\/cb300510w","article-title":"Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and nonreplicating Mycobacterium tuberculosis","volume":"8","author":"Shirude","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.tube.2016.04.011","article-title":"A comparative analysis of the DNA recombination repair pathway in mycobacterial genomes","volume":"99","author":"Singh","year":"2016","journal-title":"Tuberculosis (Edinb)."},{"key":"B161","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1126\/science.1164571","article-title":"PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release","volume":"322","author":"Singh","year":"2008","journal-title":"Science"},{"key":"B162","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.drudis.2016.09.010","article-title":"Identification and validation of novel drug targets in Mycobacterium tuberculosis","volume":"22","author":"Singh","year":"2017","journal-title":"Drug Discov. Today"},{"key":"B163","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.chembiol.2014.11.006","article-title":"The complex mechanism of antimycobacterial action of 5-Fluorouracil","volume":"22","author":"Singh","year":"2015","journal-title":"Chem. Biol."},{"key":"B164","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1021\/acsinfecdis.6b00102","article-title":"The Inosine Monophosphate Dehydrogenase, GuaB2, is a vulnerable new bactericidal drug target for tuberculosis","volume":"3","author":"Singh","year":"2017","journal-title":"ACS Infect. Dis"},{"key":"B165","doi-asserted-by":"publisher","first-page":"S200","DOI":"10.1016\/j.tube.2015.02.028","article-title":"Lead selection and characterization of antitubercular compounds using the Nested Chemical Library","author":"Sipos","year":"2015","journal-title":"Tuberculosis (Edinb)"},{"key":"B166","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejps.2015.02.017","article-title":"Identification of potential Mycobacterium tuberculosis topoisomerase I inhibitors: a study against active, dormant and resistant tuberculosis","volume":"72","author":"Sridevi","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"B167","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.bmcl.2006.02.065","article-title":"Gatifloxacin derivatives: synthesis, antimycobacterial activities, and inhibition of Mycobacterium tuberculosis DNA gyrase","volume":"16","author":"Sriram","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B168","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/prot.21457","article-title":"NAD+-dependent DNA ligase (Rv3014c) from Mycobacterium tuberculosis: novel structure-function relationship and identification of a specific inhibitor","volume":"69","author":"Srivastava","year":"2007","journal-title":"Proteins"},{"key":"B169","doi-asserted-by":"publisher","first-page":"7090","DOI":"10.1093\/nar\/gki1006","article-title":"Mycobacterium tuberculosis NAD+-dependent DNA ligase is selectively inhibited by glycosylamines compared with human DNA ligase I","volume":"33","author":"Srivastava","year":"","journal-title":"Nucleic Acids Res."},{"key":"B170","doi-asserted-by":"publisher","first-page":"30273","DOI":"10.1074\/jbc.M503780200","article-title":"NAD+-dependent DNA Ligase (Rv3014c) from Mycobacterium tuberculosis. Crystal structure of the adenylation domain and identification of novel inhibitors","volume":"280","author":"Srivastava","year":"","journal-title":"J. Biol. Chem."},{"key":"B171","doi-asserted-by":"publisher","first-page":"5977","DOI":"10.1128\/AAC.00719-13","article-title":"Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases","volume":"57","author":"Stokes","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"B172","doi-asserted-by":"publisher","first-page":"4556","DOI":"10.1016\/j.bmcl.2011.05.128","article-title":"Discovery of bacterial NAD+-dependent DNA ligase inhibitors: optimization of antibacterial activity","volume":"21","author":"Stokes","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B173","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/35016103","article-title":"A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis","volume":"405","author":"Stover","year":"2000","journal-title":"Nature"},{"key":"B174","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1179\/joc.2005.17.2.169","article-title":"In vitro activity of fluoroquinolones against Mycobacterium tuberculosis","volume":"17","author":"Sulochana","year":"2005","journal-title":"J. Chemother."},{"key":"B175","doi-asserted-by":"publisher","first-page":"6705","DOI":"10.1016\/j.bmcl.2012.08.094","article-title":"Structure-guided design, synthesis and biological evaluation of novel DNA ligase inhibitors with in vitro and in vivo anti-staphylococcal activity","volume":"22","author":"Surivet","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B176","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1021\/jm980693i","article-title":"6-Anilinouracil-based inhibitors of Bacillus subtilis DNA polymerase III: antipolymerase and antimicrobial structure-activity relationships based on substitution at uracil N3","volume":"42","author":"Tarantino","year":"","journal-title":"J. Med. Chem."},{"key":"B177","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1128\/AAC.43.8.1982","article-title":"Inhibitors of DNA polymerase III as novel antimicrobial agents against gram-positive eubacteria","volume":"43","author":"Tarantino","year":"","journal-title":"Antimicrob. Agents Chemother."},{"key":"B178","doi-asserted-by":"publisher","first-page":"e84409","DOI":"10.1371\/journal.pone.0084409","article-title":"Tricyclic GyrB\/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents","volume":"8","author":"Tari","year":"","journal-title":"PLoS ONE"},{"key":"B179","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.bmcl.2012.11.032","article-title":"Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity","volume":"23","author":"Tari","year":"","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B180","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/nar\/gkt900","article-title":"Comprehensive analysis of DNA polymerase III alpha subunits and their homologs in bacterial genomes","volume":"42","author":"Timinskas","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"B181","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.bmcl.2006.12.005","article-title":"Structure-activity relationships of 3-aminoquinazolinediones, a new class of bacterial type-2 topoisomerase (DNA gyrase and topo IV) inhibitors","volume":"17","author":"Tran","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B182","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.4155\/fmc-2016-0042","article-title":"Targeting bacterial topoisomerases: how to counter mechanisms of resistance","volume":"8","author":"Tse-Dinh","year":"2016","journal-title":"Future Med. Chem."},{"key":"B183","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1093\/jac\/dkw548","article-title":"DNA replication proteins as potential targets for antimicrobials in drug-resistant bacterial pathogens","volume":"72","author":"van Eijk","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"B184","doi-asserted-by":"publisher","first-page":"2472555217712001","DOI":"10.1177\/2472555217712001","article-title":"A High-Throughput Screening Strategy to Identify Inhibitors of SSB Protein-Protein Interactions in an Academic Screening Facility","author":"Voter","year":"2017","journal-title":"SLAS Discov."},{"key":"B185","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1021\/ja00968a057","article-title":"Plat antitumor agents. I. The isolation and structure of camptothecin, anovel alkaloidal leukemia and tumor inhibitor from camptotheca acuminata","volume":"88","author":"Wall","year":"1966","journal-title":"J. Am. Chem. Soc."},{"key":"B186","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1016\/j.bmcl.2012.04.038","article-title":"Design, synthesis and biological evaluation of potent NAD+-dependent DNA ligase inhibitors as potential antibacterial agents. Part 2: 4-amino-pyrido[2, 3-d]pyrimidin-5(8H)-ones","volume":"22","author":"Wang","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B187","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.gene.2012.11.033","article-title":"The evolutionary landscape of the Mycobacterium tuberculosis genome","volume":"518","author":"Wang","year":"2013","journal-title":"Gene"},{"key":"B188","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/j.ddmec.2010.08.002","article-title":"The role of DNA repair in M. tuberculosis pathogenesis","volume":"7","author":"Warner","year":"2010","journal-title":"Drug Disc. Tod."},{"key":"B189","doi-asserted-by":"publisher","first-page":"a021121","DOI":"10.1101\/cshperspect.a021121","article-title":"Mycobacterium tuberculosis metabolism","volume":"5","author":"Warner","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B190","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1056\/NEJMe1410977","article-title":"Shortening treatment for tuberculosis\u2013to basics","volume":"371","author":"Warner","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B191","doi-asserted-by":"publisher","first-page":"13093","DOI":"10.1073\/pnas.1002614107","article-title":"Essential roles for imuA'- and imuB-encoded accessory factors in DnaE2-dependent mutagenesis in Mycobacterium tuberculosis","volume":"107","author":"Warner","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B192","volume-title":"Global Tuberculosis Report","year":"2016"},{"key":"B193","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1021\/jm051066d","article-title":"Isothiazolopyridones: synthesis, structure, and biological activity of a new class of antibacterial agents","volume":"49","author":"Wiles","year":"","journal-title":"J. Med. Chem."},{"key":"B194","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.bmcl.2005.11.065","article-title":"Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells","volume":"16","author":"Wiles","year":"","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B195","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1128\/JB.00302-11","article-title":"UvrD2 is essential in Mycobacterium tuberculosis, but its helicase activity is not required","volume":"193","author":"Williams","year":"2011","journal-title":"J. Bacteriol."},{"key":"B196","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1039\/c7np00019g","article-title":"Opportunities for natural products in 21st century antibiotic discovery","volume":"34","author":"Wright","year":"2017","journal-title":"Nat. Prod. Rep."},{"key":"B197","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.bmcl.2004.11.016","article-title":"Active site directed inhibitors of replication-specific bacterial DNA polymerases","volume":"15","author":"Wright","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B198","doi-asserted-by":"publisher","first-page":"7639","DOI":"10.1007\/s11033-014-3654-z","article-title":"Screening essential genes of Mycobacterium tuberculosis with the pathway enrichment method","volume":"41","author":"Xu","year":"2014","journal-title":"Mol. Biol. Rep."},{"key":"B199","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.1016\/j.bmcl.2011.05.093","article-title":"7-Alkyl-N(2)-substituted-3-deazaguanines. Synthesis, DNA polymerase III inhibition and antibacterial activity","volume":"21","author":"Xu","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B200","doi-asserted-by":"publisher","first-page":"7993","DOI":"10.1073\/pnas.1700062114","article-title":"MmpL3 is the flippase for mycolic acids in mycobacteria","volume":"114","author":"Xu","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B201","first-page":"1013","article-title":"Bacterial and eukaryotic replisome machines","volume":"3","author":"Yao","year":"","journal-title":"JSM Biochem. Mol. Biol."},{"key":"B202","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3109\/10409238.2015.1125845","article-title":"Evolution of replication machines","volume":"51","author":"Yao","year":"","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"B203","volume-title":"Nargenicin Compounds and Uses thereof as Antibacterial Agents","author":"Young","year":"2016"},{"key":"B204","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ejmech.2017.04.077","article-title":"Design, synthesis and antimicrobial evaluation of novel benzimidazole-incorporated sulfonamide analogues","volume":"136","author":"Zhang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"B205","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1021\/acsmedchemlett.5b00266","article-title":"Discovery of indazole derivatives as a novel class of Bacterial Gyrase B Inhibitors","volume":"6","author":"Zhang","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"B206","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/nrd4001","article-title":"Advances in the development of new tuberculosis drugs and treatment regimens","volume":"12","author":"Zumla","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"B207","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S1473-3099(13)70328-1","article-title":"New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects","volume":"14","author":"Zumla","year":"2014","journal-title":"Lancet Infect. Dis."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fmolb.2017.00075\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,6]],"date-time":"2019-10-06T03:18:31Z","timestamp":1570331911000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fmolb.2017.00075\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,14]]},"references-count":207,"alternative-id":["10.3389\/fmolb.2017.00075"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2017.00075","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,14]]},"article-number":"75"}}